» Articles » PMID: 38970103

Exosomes: Compositions, Biogenesis, and Mechanisms in Diabetic Wound Healing

Overview
Publisher Biomed Central
Specialty Biotechnology
Date 2024 Jul 5
PMID 38970103
Authors
Affiliations
Soon will be listed here.
Abstract

Diabetic wounds are characterized by incomplete healing and delayed healing, resulting in a considerable global health care burden. Exosomes are lipid bilayer structures secreted by nearly all cells and express characteristic conserved proteins and parent cell-associated proteins. Exosomes harbor a diverse range of biologically active macromolecules and small molecules that can act as messengers between different cells, triggering functional changes in recipient cells and thus endowing the ability to cure various diseases, including diabetic wounds. Exosomes accelerate diabetic wound healing by regulating cellular function, inhibiting oxidative stress damage, suppressing the inflammatory response, promoting vascular regeneration, accelerating epithelial regeneration, facilitating collagen remodeling, and reducing scarring. Exosomes from different tissues or cells potentially possess functions of varying levels and can promote wound healing. For example, mesenchymal stem cell-derived exosomes (MSC-exos) have favorable potential in the field of healing due to their superior stability, permeability, biocompatibility, and immunomodulatory properties. Exosomes, which are derived from skin cellular components, can modulate inflammation and promote the regeneration of key skin cells, which in turn promotes skin healing. Therefore, this review mainly emphasizes the roles and mechanisms of exosomes from different sources, represented by MSCs and skin sources, in improving diabetic wound healing. A deeper understanding of therapeutic exosomes will yield promising candidates and perspectives for diabetic wound healing management.

Citing Articles

Dedifferentiated fat cells-derived exosomes (DFATs-Exos) loaded in GelMA accelerated diabetic wound healing through Wnt/β-catenin pathway.

Dong M, Ma X, Li F Stem Cell Res Ther. 2025; 16(1):103.

PMID: 40022232 PMC: 11871660. DOI: 10.1186/s13287-025-04205-9.


Advances in small extracellular vesicles: roles in the tumor microenvironment and epithelial ovarian cancer diagnosis and treatment.

Peng L, Lai Y, Cao B Front Oncol. 2025; 15:1526944.

PMID: 40008006 PMC: 11850269. DOI: 10.3389/fonc.2025.1526944.


Inflammatory memory-activated biomimetic nanovesicles regulate neutrophil plasticity and metabolic reprogramming for rapid diabetic wound healing via targeting miR-193a-5p/TLR4/JNK/P38 MAPK pathways.

Fan Y, Yang J, Xie Y, Yang X, Zhu H, Liu Y J Nanobiotechnology. 2025; 23(1):115.

PMID: 39962468 PMC: 11834291. DOI: 10.1186/s12951-025-03193-5.


Immunomodulation effects of collagen hydrogel encapsulating extracellular vesicles derived from calcium silicate stimulated-adipose mesenchymal stem cells for diabetic healing.

Lin Y, Chen Y, Liu E, Chen M, Yu M, Chen C J Nanobiotechnology. 2025; 23(1):45.

PMID: 39865263 PMC: 11770968. DOI: 10.1186/s12951-025-03097-4.


Glucose oxidase: An emerging multidimensional treatment option for diabetic wound healing.

Liao Y, Zhang Z, Zhao Y, Zhang S, Zha K, Ouyang L Bioact Mater. 2024; 44:131-151.

PMID: 39484022 PMC: 11525048. DOI: 10.1016/j.bioactmat.2024.10.006.


References
1.
Xu G, Zhang B, Ye J, Cao S, Shi J, Zhao Y . Exosomal miRNA-139 in cancer-associated fibroblasts inhibits gastric cancer progression by repressing MMP11 expression. Int J Biol Sci. 2019; 15(11):2320-2329. PMC: 6775321. DOI: 10.7150/ijbs.33750. View

2.
Lv Q, Deng J, Chen Y, Wang Y, Liu B, Liu J . Engineered Human Adipose Stem-Cell-Derived Exosomes Loaded with miR-21-5p to Promote Diabetic Cutaneous Wound Healing. Mol Pharm. 2020; 17(5):1723-1733. DOI: 10.1021/acs.molpharmaceut.0c00177. View

3.
Alshabibi M, Khatlani T, Abomaray F, Alaskar A, Kalionis B, Messaoudi S . Human decidua basalis mesenchymal stem/stromal cells protect endothelial cell functions from oxidative stress induced by hydrogen peroxide and monocytes. Stem Cell Res Ther. 2018; 9(1):275. PMC: 6202803. DOI: 10.1186/s13287-018-1021-z. View

4.
Katoh M . Therapeutics targeting angiogenesis: genetics and epigenetics, extracellular miRNAs and signaling networks (Review). Int J Mol Med. 2013; 32(4):763-7. PMC: 3812243. DOI: 10.3892/ijmm.2013.1444. View

5.
Zhou X, Cao H, Guo J, Yuan Y, Ni G . Effects of BMSC-Derived EVs on Bone Metabolism. Pharmaceutics. 2022; 14(5). PMC: 9146387. DOI: 10.3390/pharmaceutics14051012. View